Front Cardiovasc Med. 2026 May 25;13:1816772. doi: 10.3389/fcvm.2026.1816772. eCollection 2026.
ABSTRACT
OBJECTIVE: To evaluate the safety, hemodynamic efficacy, and short-term outcomes of CorVad mechanical circulatory support as a bridge to left ventricular assist device (LVAD) therapy for cardiogenic shock and the changes in related hemolysis indicators.
METHODS: We retrospectively analyzed three patients with Society for Cardiovascular Angiography and Interventions (SCAI) stage D Cardiogenic shock (CS) admitted between November 2024 and May 2025 to the First Affiliated Hospital of Anhui Medical University. All received CorVad support and were bridged to LVAD. Hemodynamic parameters, short-term prognosis, and dynamic changes in hemoglobin (Hb), hematocrit (Hct) and Indirect bilirubin within 24 h post-implantation were assessed.
RESULTS: CorVad support led to rapid improvements in mean arterial pressure, cardiac output, and cardiac index, accompanied by a marked reduction in lactate. All three patients successfully underwent elective LVAD implantation without procedural complications or in-hospital mortality. All patients remained alive and ambulatory at 30-day and 3-month follow-up. Within 24 h post-implantation, Hb, Hct declined modestly and indirect bilirubin levels have slightly increased, suggesting mild hemolysis or transient hemodilution, without severe hemolysis-related complications.
CONCLUSION: CorVad provides effective and timely hemodynamic rescue in patients with CS, enabling safe transition to durable LVAD implantation, with favorable short-term prognosis. Serial monitoring of hemolysis-related indicators is required postoperatively to identify and manage potential hemolysis risks at an early stage.
PMID:42267098 | PMC:PMC13243228 | DOI:10.3389/fcvm.2026.1816772